Brief: Avalo Completes Enrollment Of 80 Patients In Phase 2 Asthma Study

Avalo Therapeutics

17/01/2023 12:15

Jan 17 (Reuters) - Avalo Therapeutics Inc  AVTX.O :
    * AVALO ANNOUNCES IT HAS COMPLETED TARGETED ENROLLMENT OF 80
PATIENTS IN PHASE 2 PEAK TRIAL OF AVTX-002 IN NON-EOSINOPHILIC
ASTHMA
    * AVALO THERAPEUTICS INC - WILL ALLOW ADDITIONAL PATIENTS
CURRENTLY IN RUN-IN PERIOD TO COMPLETE ENROLLMENT
    * AVALO THERAPEUTICS INC - TOPLINE DATA FROM CLINICAL TRIAL
ARE
EXPECTED TO BE RELEASED IN Q2 OF 2023

Source text for Eikon:  ID:nGNX5rPNFF 
Further company coverage:  AVTX.O 
 ((Reuters.Briefs@thomsonreuters.com;))